These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 9406718)
21. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907 [TBL] [Abstract][Full Text] [Related]
22. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. Muthuswamy MS; Roberson PL; Ten Haken RK; Buchsbaum DJ Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):165-72. PubMed ID: 8641915 [TBL] [Abstract][Full Text] [Related]
23. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule. Ceriani RL; Blank EW Cancer Res; 1988 Aug; 48(16):4664-72. PubMed ID: 3396015 [TBL] [Abstract][Full Text] [Related]
24. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147 [TBL] [Abstract][Full Text] [Related]
25. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230 [TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Shih LB; Xuan H; Aninipot R; Stein R; Goldenberg DM Cancer Res; 1995 Dec; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360 [TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG. Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586 [TBL] [Abstract][Full Text] [Related]
28. Targeting and therapy of human glioma xenografts in vivo using radiolabeled antibodies. Williams JA; Edwards JA; Wessels BW; Dillehay LE; Wanek PM; Poggenburg JK; Wharam MD; Order SE; Klein JL Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):633-42. PubMed ID: 2170301 [TBL] [Abstract][Full Text] [Related]
29. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714 [TBL] [Abstract][Full Text] [Related]
30. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate. Beatty BG; Kuhn JA; Hui TE; Fisher DR; Williams LE; Beatty JD Cancer; 1994 Feb; 73(3 Suppl):958-65. PubMed ID: 8306285 [TBL] [Abstract][Full Text] [Related]
31. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy. Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611 [TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441 [TBL] [Abstract][Full Text] [Related]
33. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425 [TBL] [Abstract][Full Text] [Related]
34. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566 [TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345 [TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model. Kairemo K; Ljunggren K; Strand SE; Hiltunen J; Penttilä P; Nikula T; Laine A; Wahlström T Acta Oncol; 1993; 32(7-8):801-5. PubMed ID: 8305229 [TBL] [Abstract][Full Text] [Related]
40. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Molthoff CF; Pinedo HM; Schlüper HM; Rutgers DH; Boven E Int J Cancer; 1992 Apr; 51(1):108-15. PubMed ID: 1563830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]